Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/AZGP1_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/AZGP1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/AZGP1_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/AZGP1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/AZGP1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/AZGP1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00024839 | Breast | Precancer | antigen processing and presentation of endogenous peptide antigen | 8/1080 | 19/18723 | 5.10e-06 | 1.53e-04 | 8 |
GO:00198839 | Breast | Precancer | antigen processing and presentation of endogenous antigen | 9/1080 | 26/18723 | 8.75e-06 | 2.34e-04 | 9 |
GO:00027117 | Breast | Precancer | positive regulation of T cell mediated immunity | 12/1080 | 56/18723 | 6.72e-05 | 1.35e-03 | 12 |
GO:00019168 | Breast | Precancer | positive regulation of T cell mediated cytotoxicity | 8/1080 | 29/18723 | 1.73e-04 | 2.83e-03 | 8 |
GO:00480029 | Breast | Precancer | antigen processing and presentation of peptide antigen | 12/1080 | 62/18723 | 1.89e-04 | 3.04e-03 | 12 |
GO:00198859 | Breast | Precancer | antigen processing and presentation of endogenous peptide antigen via MHC class I | 6/1080 | 17/18723 | 2.59e-04 | 3.83e-03 | 6 |
GO:00024749 | Breast | Precancer | antigen processing and presentation of peptide antigen via MHC class I | 7/1080 | 28/18723 | 8.46e-04 | 9.82e-03 | 7 |
GO:00027094 | Breast | Precancer | regulation of T cell mediated immunity | 13/1080 | 85/18723 | 1.12e-03 | 1.23e-02 | 13 |
GO:00019146 | Breast | Precancer | regulation of T cell mediated cytotoxicity | 8/1080 | 39/18723 | 1.48e-03 | 1.53e-02 | 8 |
GO:00019134 | Breast | Precancer | T cell mediated cytotoxicity | 9/1080 | 49/18723 | 1.74e-03 | 1.74e-02 | 9 |
GO:00018956 | Breast | Precancer | retina homeostasis | 12/1080 | 79/18723 | 1.82e-03 | 1.79e-02 | 12 |
GO:00718064 | Breast | Precancer | protein transmembrane transport | 10/1080 | 59/18723 | 1.86e-03 | 1.81e-02 | 10 |
GO:00018948 | Breast | Precancer | tissue homeostasis | 27/1080 | 268/18723 | 3.49e-03 | 2.90e-02 | 27 |
GO:00024563 | Breast | Precancer | T cell mediated immunity | 14/1080 | 109/18723 | 3.97e-03 | 3.15e-02 | 14 |
GO:0002821 | Breast | Precancer | positive regulation of adaptive immune response | 14/1080 | 112/18723 | 5.08e-03 | 3.82e-02 | 14 |
GO:004800213 | Breast | IDC | antigen processing and presentation of peptide antigen | 18/1434 | 62/18723 | 5.28e-07 | 2.59e-05 | 18 |
GO:000248314 | Breast | IDC | antigen processing and presentation of endogenous peptide antigen | 9/1434 | 19/18723 | 4.03e-06 | 1.43e-04 | 9 |
GO:001988313 | Breast | IDC | antigen processing and presentation of endogenous antigen | 10/1434 | 26/18723 | 1.14e-05 | 3.08e-04 | 10 |
GO:00198829 | Breast | IDC | antigen processing and presentation | 20/1434 | 106/18723 | 1.41e-04 | 2.49e-03 | 20 |
GO:001988513 | Breast | IDC | antigen processing and presentation of endogenous peptide antigen via MHC class I | 7/1434 | 17/18723 | 1.49e-04 | 2.61e-03 | 7 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
AZGP1 | SNV | Missense_Mutation | rs779480370 | c.523N>A | p.Val175Met | p.V175M | P25311 | protein_coding | deleterious(0.01) | possibly_damaging(0.852) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
AZGP1 | SNV | Missense_Mutation | novel | c.472N>A | p.Asp158Asn | p.D158N | P25311 | protein_coding | deleterious(0.01) | possibly_damaging(0.778) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
AZGP1 | SNV | Missense_Mutation | rs770260118 | c.346N>A | p.Val116Ile | p.V116I | P25311 | protein_coding | tolerated(0.2) | benign(0) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
AZGP1 | SNV | Missense_Mutation | | c.297N>T | p.Glu99Asp | p.E99D | P25311 | protein_coding | tolerated(0.62) | benign(0.001) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
AZGP1 | SNV | Missense_Mutation | novel | c.193N>T | p.Asp65Tyr | p.D65Y | P25311 | protein_coding | deleterious(0.01) | possibly_damaging(0.834) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
AZGP1 | SNV | Missense_Mutation | rs375716148 | c.328G>A | p.Asp110Asn | p.D110N | P25311 | protein_coding | tolerated(0.06) | benign(0.122) | TCGA-BK-A6W3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
AZGP1 | SNV | Missense_Mutation | | c.757N>T | p.Asp253Tyr | p.D253Y | P25311 | protein_coding | deleterious(0.02) | benign(0.397) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AZGP1 | SNV | Missense_Mutation | rs199572012 | c.751C>T | p.Arg251Trp | p.R251W | P25311 | protein_coding | tolerated(0.12) | benign(0.005) | TCGA-D1-A174-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
AZGP1 | SNV | Missense_Mutation | novel | c.307N>T | p.Asp103Tyr | p.D103Y | P25311 | protein_coding | deleterious(0) | possibly_damaging(0.906) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
AZGP1 | SNV | Missense_Mutation | novel | c.318N>T | p.Glu106Asp | p.E106D | P25311 | protein_coding | tolerated(1) | benign(0) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |